Our network
ABX-CRO is an independent international Contract Research Organization, providing standard and specialised phase I – III clinical trial services with emphasis on oncology and molecular imaging. Due to its history, ABX-CRO has retained a strong focus in oncology, neuroscience, and imaging indications. Thanks to our special interdisciplinary set-up with a team of research physicians, pharmacologists, radiopharmacists, pre-clinical experts, imaging physicists, and computer scientists, ABX-CRO is able to successfully conduct even most unusual trials (e.g., imaging trials in psychiatric patients), with the same reliability as standard protocols.
Discover DRIVE-MRT, our integrated solution for Molecular RadioTherapy in partnership with ABX-CRO
Abzena is the leading end-to-end integrated CDMO for Antibody Drug Conjugates (ADCs) and complex biologic molecules with headquarters in San Diego, CA and additional centres of excellence in Bristol, PA and Cambridge, UK.
Abzena has extensive experience in developing Biologics and Bioconjugates, and provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry.
Discover DRIVE-Biologics, our integrated solution for Biologics in partnership with Abzena.
Assay.Works is a contract research organization (CRO) providing research services to pharmaceutical/biotech companies and academic organizations in form of fee-for-service work.
His mission is to accelerate our partner’s research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. He combines scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.
Biofortis is a unique full service CRO providing Nutrition Clinical Trials, Microbiome Investigation and Data Science for Human and Animal Health.
Over the past two decades, Biofortis has designed, organized and executed more than 1000 projects to help academics and sponsors from the pharma, biotech and food tech industries to substantiate their health claims.
By virtue of our unique expertise in microbiome, we help you to accelerate your microbiome-health innovation projects.
The Service for the Study of Prions and Atypical Infections (SEPIA) in CEA has the mission of developing and evaluating research strategies in response to public health problems related to prions and related or atypical pathogens.
Prion-type mechanisms are now considered to underlie the main human neurodegenerative diseases, foremost among which is Alzheimer’s disease.
CheMatech is a unique company in Europe specialized in the design and synthesis of chelators, particularly DOTA and NOTA derivatives precursors of MRI contrast agents, PET and SPECT tracers and therapeutic agents for radioimmunotherapy.
CheMatech activity is divided into three parts : Custom synthesis of chelating agents, and Participation in Joint Research Programs (H2020, Marie Curie, ANR, …)
Discover DRIVE-MRT, our integrated solution for Molecular RadioTherapy in partnership with Chematech
Covalab is a French biotechnology company specialized in antibody engineering, founded in 1995. It is expert in the design and development of antibody (polyclonal, monoclonal scFv, FAb, VHH, recombinant antibodies) using antigen or DNA immunization. In addition, it offers purified and labeling antibodies, peptide synthesis for research use, diagnostic and therapeuthic.
As a producer, it supplies many distributors to sale our innovative and high quality antibodies.
Discover DRIVE-MRT, our integrated solution for Molecular RadioTherapy in partnership with Covalab.
Cynbiose is a specialty Contract Research Organization (CRO) unique in Europe. The company is specialized in preclinical research services with a core expertise and focus on the non-human primate (NHP) model. They also develop innovative clinically relevant models across multiple therapeutic areas to accelerate the discovery of drug candidates.
They perform exploratory pharmacokinetics and pharmacodynamics studies, early (non-GLP) safety studies, hybrid exploratory designs, and efficacy studies to bridge the gap between preclinical and clinical development.
ERBC (European Research Biology Center) is a European leader in non-clinical studies. Based in Baugy (France) and Roma (Italy), ERBC provides all services from preclinical proof-of-concept to market of any type of drug candidate or chemical compound.
IDMIT, for “Infectious Disease Models and Innovative Therapies” is a national Research and Technological infrastructure for biology and health dedicated to preclinical research on infectious diseases.
IDMIT is located both in the CEA site of Fontenay-aux-Roses and on the Kremlin-Bicêtre hospital site, France.
Iktos is an innovative company specializing in the development of artificial intelligence (AI) solutions applied to chemical research, more specifically medicinal chemistry and new drug design.
The use of Iktos technology platform enables major productivity gains in upstream pharmaceutical R&D.
Discover DRIVE-SM, our integrated solution for Small Molecule in partnership with Iktos.
As the specialized provider, the services PharmaLex offers are essential to enable companies to maximize their development processes and reduce their time to market.
Their solutions consist of core services, which are tailored to address each of your unique requirements. They also have extensive program management expertise, a key success factor within their service solutions.
PhinC Development is launched in 2008 as a CRO specialized in pharmacometrics modeling and simulation for the development of drug candidates. PhinC’s mission is to take advantage of all research data and develop predictive pharmacological models specific to drug candidates mainly developed by Biotech companies to help save time and costs while ensuring the robustness of the study design.
VIS aims to realize a society where every patient can look forward to a brighter future through next-generation small molecule drug discovery targeting mRNA. VIS, as a pathfinder in mRNA-targeted drug discovery, has established a fully integrated drug discovery platform, ibVIS®, including lots of in-house software with rule-based AI, and has been conducting drug discovery research in collaboration with pharmaceutical companies since 2018 to create mRNA-targeted small molecule drugs for therapeutic areas such as oncology, neurology, and infectious diseases.
Established in 2009, VIVEXIA is a CRO (Contract Research Organization) focusing on life sciences and health. Their actions and motivation are focused on combatting antimicrobial resistant bacteria. To this aim, they specialized in the creation of humanized or non-humanized preclinical infection models that are designed for the evaluation of anti-infective therapies.
ZoBio has built a class-leading platform that provides a complete solution for Fragment Based Drug Discovery to their clients. Their gene-to-lead capabilities include: protein production, biophysical and functional assays, structural biology (crystallography, NMR & cryoEM) and fragment focused medicinal chemistry. The team of 46 people brings its dedication and expertise to help solve your largest drug discovery challenges. More information: http://www.zobio.com
Our memberships
